



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, May 19th, 2016
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, PharmD
Clinton Sheffield, MD
Clayton Grace, RPh
Susan Siegfried, MD

Keith Tolman, MD
Beth Johnson, RPh
Ellie Brownstein, MD

Committee Members Excused:

Jameson Rice, PharmD

Elizabeth Young, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Alyssa Martin, RN
Merelynn Berrett, RN
Heather Santacruz, RN

Chad Hope, PharmD
Megan Schlappi, CPhT

University of Utah Drug Regimen Review Center Staff Present:

Melissa Archer, PharmD

Other Individuals Present:

Becky Gonzales, Viiv Healthcare
Rob Bigham, Shire
Abril Atherton
Jeremy Christensen, DSAMH
Sherri Wittwer, NAMI

Pat Trifunov, Tris Pharma
Cody Ball, Select Health
Todd Thatcher, Valley Behavioral Health
Roy Lindfield, Sunovion

Meeting conducted by: Clinton Sheffield, MD

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign in.
2. **Review and Approval of April Minutes:** Keith Tolman made a motion to approve the minutes from April. Bryan Larson seconded the motion. All in favor.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last month to discuss Xyrem. Prior Authorization criteria was established.
4. **ADHD Stimulants:** Melissa Archer presented a review of ADHD Stimulants. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:**
 - a. Pat Trifunov- Pat Trifunov discussed the product Dyanavel XR. Dyanaval XR is the first amphetamine oral solution on the market and benefits those who may have trouble swallowing tablets.
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States Medicaid programs.
7. **Board Discussion**
 - a. Chad Hope asked if there was evidence that Vyvanse is more effective than the other medications, as it appeared that there has been an increase in utilization of Vyvanse in the Medicaid population recently. Melissa Archer responded that the Oregon Report does not provide any comparative information between the different drugs.
 - b. Ellie Brownstein had questions about current prior authorization criteria on stimulants in regards to the age limits posted.
 - c. Bryan Larson reminded the board that putting age limits or prior authorization criteria on these medications is a DUR function, not P&T.
 - d. Ellie Brownstein made a motion to have the DUR board review ADHD stimulants. Clinton Sheffield seconded. All in Favor.
 - e. Keith Tolman made a motion that all drugs in this class are equally safe and effective. Bryan Larson seconded the motion. All in Favor.
 - f. Keith Tolman recommended that all of the drugs in this class be placed on the PDL and then the prescribers can choose what medication is best for the patient.
 - g. Susan Seigfried made a motion that there be at least one formulation from both the amphetamine and methylphenidate sub-class that does not have to be taken as a single, intact entity as preferred on the PDL. Ellie Brownstein seconded. All in Favor.
 - h. Clinton Sheffield made a motion to include at least one short-acting and one long-acting formulation as preferred on the PDL.
 - i. The board asked if they should be discussing non-stimulant medications that are used for ADHD like clonidine or guanfacine. Chad Hope let them know that the legislation specifically stated that only stimulant medications are to be discussed.
8. **Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Keith Tolman seconded. All in Favor.
9. Next meeting is scheduled for June 16, 2016. Newer Anticonvulsant Agents will be discussed.

Minutes prepared by Megan Schlappi, CPhT

Recording available upon request, send email to medicaidpharmacy@utah.gov